Literature DB >> 8534931

Liposomal muramyl tripeptide upregulates adhesion molecules on the surface of human monocytes.

T Asano1, B W McIntyre, J L Bednarczyk, J N Wygant, E S Kleinerman.   

Abstract

We previously demonstrated that liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (L-MTP-PE), a biologic response modifier now undergoing phase III clinical trial in osteosarcoma, upregulated monocyte expression of several cytokines' mRNA and the subsequent production of these proteins. In the present work, we investigated whether L-MTP-PE upregulated adhesion molecules on the surface of normal human monocytes. Flow-cytometric analysis showed that several subunits of the integrins, including alpha L, alpha 5, and beta 1 subunits, and intercellular adhesion molecule-1 on the monocytes were upregulated following their stimulation with 2 micrograms/ml L-MTP-PE for 24 h. Anti-alpha L antibodies blocked monocyte-mediated tumor cell killing stimulated by L-MTP-PE. We conclude that L-MTP-PE also stimulates the increase of several molecules on the monocyte cell surface. These adhesion molecules may contribute to the increased activation of monocyte-mediated tumor cell killing seen following L-MTP-PE exposure.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8534931

Source DB:  PubMed          Journal:  Oncol Res        ISSN: 0965-0407            Impact factor:   5.574


  5 in total

Review 1.  Mifamurtide: a review of its use in the treatment of osteosarcoma.

Authors:  James E Frampton
Journal:  Paediatr Drugs       Date:  2010-06       Impact factor: 3.022

Review 2.  Mifamurtide for the treatment of nonmetastatic osteosarcoma.

Authors:  Kosei Ando; Kanji Mori; Nedège Corradini; Françoise Redini; Dominique Heymann
Journal:  Expert Opin Pharmacother       Date:  2011-02       Impact factor: 3.889

3.  A pharmacokinetic, pharmacodynamic, and electrocardiographic study of liposomal mifamurtide (L-MTP-PE) in healthy adult volunteers.

Authors:  Karthik Venkatakrishnan; William G Kramer; Timothy W Synold; Daniel B Goodman; Evin Sides; Cristina Oliva
Journal:  Eur J Clin Pharmacol       Date:  2012-03-30       Impact factor: 2.953

Review 4.  New paradigms for therapy for osteosarcoma.

Authors:  Rajaram Nagarajan; Denis Clohisy; Brenda Weigel
Journal:  Curr Oncol Rep       Date:  2005-11       Impact factor: 5.075

5.  The Current and Future Therapies for Human Osteosarcoma.

Authors:  Joseph D Lamplot; Sahitya Denduluri; Jiaqiang Qin; Ruidong Li; Xing Liu; Hongyu Zhang; Xiang Chen; Ning Wang; Abdullah Pratt; Wei Shui; Xiaoji Luo; Guoxin Nan; Zhong-Liang Deng; Jinyong Luo; Rex C Haydon; Tong-Chuan He; Hue H Luu
Journal:  Curr Cancer Ther Rev       Date:  2013-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.